<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584737</url>
  </required_header>
  <id_info>
    <org_study_id>1001</org_study_id>
    <nct_id>NCT03584737</nct_id>
  </id_info>
  <brief_title>Point-of-Care Immunoassay for Detection of Bacterial Sinusitis</brief_title>
  <official_title>Multi-Center Study of a Point-of-Care Immunoassay for the Detection of Bacterial Sinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ENTvantage Dx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beaufort</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ENTvantage Dx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the performance of a rapid, point-of-care in vitro&#xD;
      diagnostic device (Sinu-Test®) for the qualitative detection of the three most common&#xD;
      pathogens responsible for causing bacterial sinusitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucous specimens will be collected from patients displaying symptoms of acute bacterial&#xD;
      sinusitis enrolled by primary care and/or otolaryngology clinics in the United States. Health&#xD;
      care professionals not having endoscopy certification will collect specimens using the&#xD;
      Entvantage sample collection device. Health care professionals with nasal endoscopy&#xD;
      certification or specialty training will collect comparator specimens using an endoscope.&#xD;
      Untrained operators with a range of education and training (primary care physician,&#xD;
      otolaryngologist, physician assistant, nurse practitioner, registered nurse or other&#xD;
      healthcare professional), will perform the Sinu-Test® lateral flow assay in an outpatient&#xD;
      setting. Mucous samples will be tested for the presence of 3 bacterial pathogens responsible&#xD;
      for sinusitis using the Sinu-Test® in the clinic and by a composite comparator method&#xD;
      comprised of standard quantitative bacterial culture with identification (matrix-assisted&#xD;
      laser desorption/ionization-Time of Flight (MALDI-TOF) mass spectrometry instrument) and&#xD;
      semiquantitative real-time polymerase chain reaction (real-time PCR) of the residual culture&#xD;
      sample and the Sinu-Test® residual swab performed by a central laboratory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity (positive predictive agreement) and specificity (negative predictive agreement) of the diagnostic device</measure>
    <time_frame>Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>Assessment of the true positive and true negative rate of the point-of-care test device relative to the composite reference standard for each of the 3 bacterial microorganisms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value (PPV) and negative predictive value (NPV)</measure>
    <time_frame>Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>Positive predictive value is the probability that subjects with a positive point-of-care test truly have the bacteria present. Negative predictive value is the probability that subjects with a negative point-of-care test truly do not have the bacteria present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive likelihood ratio (LR+) and negative likelihood ratio (LR-)</measure>
    <time_frame>Cumulation of one-time subject sample results obtained in 20-30 minutes for point-of-care test and 3-5 days for lab results</time_frame>
    <description>LR+ is equivalent to the probability of a true positive result divided by the probability of a false positive result. LR- is equivalent to the probability of a false negative result divided by the probability of a true negative result.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Sinusitis Bacterial</condition>
  <arm_group>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
    <description>Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>rapid in vitro diagnostic test</intervention_name>
    <description>IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)</description>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
    <other_name>Sinu-Test®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>bacterial culture</intervention_name>
    <description>Quantitative bacterial culture assay with isolate identification by MALDI-TOF.</description>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PCR assay</intervention_name>
    <description>Semiquantitative real-time PCR assay</description>
    <arm_group_label>Symptomatic for bacterial sinusitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      nasal mucus in buffer solution&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at least 18 years of age with symptoms of bacterial sinusitis from primary care&#xD;
        clinics and otolaryngology clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets definition of acute sinusitis by Infectious Disease Society of America (2012)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic sinusitis&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Patients treated with antibiotics currently or within the previous 30 days.&#xD;
&#xD;
          -  Subjects with a prior history of sinus surgery will be excluded due to the&#xD;
             modification of sinonasal anatomy.&#xD;
&#xD;
          -  Primary immunodeficiencies, as self-reported&#xD;
&#xD;
               -  Combined variable immunodeficiency&#xD;
&#xD;
               -  Immunodeficiency with reduced immunoglobulin G (IgG) and immunoglobulin A&#xD;
                  (IgA)-bearing cells&#xD;
&#xD;
               -  Kartagener Syndrome (ciliary dyskinesia)&#xD;
&#xD;
               -  Agammaglobulinemia&#xD;
&#xD;
               -  Sickle cell disease&#xD;
&#xD;
          -  Acquired immunodeficiencies, as self-reported&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Radiation therapy&#xD;
&#xD;
               -  Transplantation&#xD;
&#xD;
               -  Asplenia&#xD;
&#xD;
               -  HIV&#xD;
&#xD;
               -  Poorly controlled Diabetes mellitus&#xD;
&#xD;
          -  Cognitive impairment resulting in the inability to provide informed consent.&#xD;
&#xD;
          -  Special groups, such as children under the age of 18, and men and women who are in&#xD;
             prison will not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Busch</last_name>
    <role>Study Director</role>
    <affiliation>Beaufort</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elisa Maldonado-Holmertz</last_name>
    <phone>+1-512-431-6069</phone>
    <email>elisa@entvantagedx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillcrest Medical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>321-999-7616</phone>
    </contact>
    <investigator>
      <last_name>John Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ENT Allergy &amp; Associates of South Florida</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>561-939-0157</phone>
    </contact>
    <investigator>
      <last_name>John Lanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-934-8424</phone>
    </contact>
    <investigator>
      <last_name>Adil Fatakia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-470-7974</phone>
    </contact>
    <investigator>
      <last_name>Todd Schaeffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimed Research/Ohio Sinus Institute</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-430-3030</phone>
    </contact>
    <investigator>
      <last_name>Boris Karanfilov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kelsey-Seybold Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-442-1224</phone>
    </contact>
    <investigator>
      <last_name>Etan Weinstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 19, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute sinusitis</keyword>
  <keyword>bacterial sinusitis</keyword>
  <keyword>point-of-care</keyword>
  <keyword>in vitro diagnostic device (IVD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

